Age-related mild cognitive deficit: A ready-to-use concept?

Dialogues in Clinical Neuroscience

Volumn 5, Issue 1, 2003, Pages 61-76

  Gilles, Christian ^a  

^a FORENAP   (France)

Author keywords

Aging; Alzheimer's disease; Cognition; Dementia; Treatment

Indexed keywords

APOLIPOPROTEIN E; CHOLINERGIC RECEPTOR STIMULATING AGENT;

AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; COGNITION; COGNITIVE DEFECT; CONCEPT FORMATION; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; FOLLOW UP; GENOTYPE; HUMAN; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREVALENCE; QUANTITATIVE ANALYSIS;

EID: 0038755540     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168-1174.
2. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
3. Christensen H. What cognitive changes can be expected with normal aging? Aust N Z J Psychiatry 2001;35:768-775.
4. Johansson B, Zarit S, Berg S. Changes in cognitive functioning of the oldest old. J Gerontol. 1992;47:P75-P80.
5. Howieson DB, Dame A, Camicioli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc. 1997;45:584-589.
6. Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurot. 1998;55:395-401.
7. Wilson RS, Beckett LA, Bennett DA, Albert S, Evans DA. Change in cognitive function in older persons from a community population. Arch Neurol. 1999;56:1274-1279.
8. Silwinski M, Lipton RB, Buschke H, Stewart W. The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J Gerontol. 1996;51B:P217-P225.
9. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101-118.
10. Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J. 1962;86:257-260.
11. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
12. Gurland BJ, Dean L, Copeland J, Gurland R, Golden R. Criteria for diagnosis of dementia in the community elderly. Gerontologist. 1982;22:180-186.
13. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139.
14. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry. 1986;149:698-709.
15. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon SG. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical changes. Report of a National Institute of Mental Health Work Group. Dev Neuropsychol. 1986;2:261-276.
16. Bradford RC, La Rue A. Criterion for diagnosing age-associated memory impairment: proposed improvement from the field. Dev Neuropsychol. 1989;5:298-306.
17. Zaudig M. A new systematic method of measurement and diagnosis of "mild cognitive impairment" and dementia according to ICD-10 and DSM-III-R criteria. Int Psychogeriatr. 1992;4(suppl 2):203-219.
18. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva, Switzerland: World Health Organization; 1993.
19. Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr. 1994;6:63-68.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
21. Petersen RC, Smith GE, Ivnik RL, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
22. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol. 1995;52:612-619.
23. Teng EL. The modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48:314-318.
24. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793-1796.
25. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Komken E. Mild cognitve impairment. Clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
26. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameters: early detection of dementia. Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.
27. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
28. Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62:281-288.
29. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
30. Weintraub S, Baratz R, Mesulam MM. Daily living activities in the assessment of dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ, eds. Alzheimer's Disease: A Report of Progress in Research. New York, NY: Raven Press; 1982:189-192.
31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
32. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24:637-639.
33. Morris JC. The clinical dementia rating: current version and scoring rules. Neurology. 1993;43:2412-2414.
34. Richards M, Touchon J, Ledesert B, Ritchie K. Cognitive decline in ageing: are AAMI and AACD distinct entities? Int J Geriat Psychiatry. 1999;14:534-540.
35. Schröder J, Kratz B, Pantel J, Minnemann E, Lehr U, Sauer H. Prevalence of mild cognitive impairment in an elderly community sample. J Neural Transm. 1998;(suppl 54):51-59.
36. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment. A population-based validation study. Neurology. 2001;56:37-42.
37. Morris JC, Storandt M, Miller JP et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
38. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326-335.
39. Kachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097-1105.
40. Morris JC, McKeel DW, Storandt M, et al. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathological distinction from normal aging. Neurology. 1991;41:469-478.
41. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991;12:295-312.
42. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58:1395-1402.
43. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469-490.
44. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49:202-213.
45. Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol. 2002;51:182-189.
46. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
47. Mirra SS, Heyman D, McKeel SM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
48. Chu Y, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH. Down-regulation of trkA mRNA within nucleus basalis of Meynert neurons in individuals with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2001;437:296-307.
49. Mufson EJ, Ma SY, Dills J, et al. Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002;443:136-153.
50. Nielsen H, Lolk A, Kragh-Sorensen P. Age-associated memory impairment - pathological memory decline or normal aging? Scand J Psychol. 1998;39:33-37.
51. Hänninen T, Hallikainen M, Koivisto K, et al. A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. J Am Geriatr Soc. 1995;43:1007-1015.
52. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321-328.
53. Small GW, La Rue A, Komo S, Kaplan A. Mnemonics usage and cognitive decline in age-associated memory impairment. Int Psychogeriatr. 1997;9:47-56.
54. Wolf H, Grunwald M, Ecke GM, et al. The prognosis of mild cognitive impairment in the elderly. J Neural Transm. 1998;54(suppl):31-50.
55. McKelvey R, Bergman H, Stern J, Rush C, Zahirney G, Chertkow H. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci. 1999;26:23-28.
56. Berent S, Giordani B, Foster NL, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res. 1999;33:7-16.
57. Bozoki A, Giordani B, Heidenbrink JL, Berent S, Foster NL. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol. 2001;58:411-416.
58. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198-205.
59. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594-1599.
60. Johansson B, Zarit SH. Early cognitive markers of the incidence of dementia and mortality: a longitudinal study of the oldest old. Int J Geriatr Psychiatry. 1997;12:53-59.
61. Palmer K, Wang HX, Bäckman L, Winblad B, Fratiglioni L. Differential evolution of cognitive impairment in nodemented older persons: results from the Kungsholmen project. Am J Psychiatry. 2002;159:436-442.
62. Meyer JS, Xu G, Thornby J, Chowdhury M, Quach M. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. J Neurol Sci. 2002;201:19-25.
63. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675-680.
64. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
65. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
66. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke. 2002;33:1981-1985.
67. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006-1009.
68. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46:661-665.
69. Tierney MC, Szalai JP, Snow WG, Fisher RH. The prediction of Alzheimer's disease: the role of patients and informant perceptions of cognitive deficits. Arch Neurol. 1996;53:423-427.
70. Tuokko H, Frerichs RJ. Cognitive impairment with no dementia (CIND): longitudinal studies, the findings, and the issues. Clin Neuropsychol. 2000;14:504-525.
71. Braak H, Braak E. Neuropathologic staging of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239-259.
72. Laakso MP. Structural imaging in cognitive impairment and the dementias: an update. Curr Opin Neurol. 2002;15:415-421.
73. Du A, Schuff N, Amend D, et al. MRI of entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;71:441-447.
74. Wolf H, Grunwald M, Kruggel F, et al. Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly. NeurobiolAging. 2001;22:177-186.
75. Bottino CM, Castro CC, Gomes RL, Buchpiguel CA, Marchetti RL, Neto MR. Volumetric MRI measurements can differentiate Alzheimer's disease, mild cognitive impairment, and normal aging. Int Psychogeriatr. 2002;14:59-72.
76. Visser PJ, Scheltens P, Verhey FRJ, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol. 1999;2146:477-485.
77. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529-539.
78. Hampel H, Teipel SJ, Bayer W. Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. J Neurol Sci. 2002;194:15-19.
79. Grundman M, Sencakova D, Jack CR, et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002;19:23-27.
80. Jack CR, Petersen RC, Xu YC, et al. Rates of hippocampal atrophy correlates with change in clinical status in aging and AD. Neurology. 2000;55:484-489.
81. de Leon M, George A, Convit A, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol. 1993;14:897-906.
82. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397-1403.
83. Killiany RJ, Gomez-isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430-439.
84. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22:747-454.
85. Convit A, de Asis J, de Leon MJ, et al. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging. 2000;21:19-26.
86. De Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and subjective cognitive dysfunction. The Rotterdam Scan study. Neurology. 2001;56:1539-1545.
87. Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, Tilvis R. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol. 1993;50:818-824.
88. Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriat Psychiatry. 2000;15:803-812.
89. Jelic V, Nordberg A. Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord. 2000;14(suppl 1):5109-5113.
90. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942-947.
91. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
92. Small GW, Ercoli LM, Silverman DHS, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:6037-6042.
93. Minoshima S, Giordani B, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
94. Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med. 2000;41:1155-1162.
95. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurology. 2002;2:9-14.
96. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology. 1998;50:1563-1571.
97. Celsis P, Agniel A, Cardebat D, Démonet JF, Ousset PJ, Puel M. Age-related cognitive decline: a clinical entity? A longitudinal study of cerebral blood flow and memory performance. J Neurol Neurosurg Psychiatry. 1997;62:601-608.
98. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851-855.
99. Small GW, LaRue A, Komo S, Kaplan A, Mandelkern MA. Predictors of cognitive changes in middle-aged and older adults with memory loss. Am J Psychiatry. 1995;152:1757-1764.
100. Reuter-Lorenz P. New visions of the aging mind and brain. Trends Cogn Sci. 2002;6:394-400.
101. Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease. Neurology. 1996;46:692-700.
102. Woodard JL, Grafton ST, Votaw JR, Green RC, Dobraski ME, Hoffman JM. Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease. Neuropsychology. 1998;12:491-504.
103. Saykin AJ, Flashman LA, Frutiger SA, et al. Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of functional MRI activation. J Int Neuropsychol Soc. 1999;5:377-392.
104. Bäckman L, Andersson JLR, Nyberg L, Winblad B, Nordberg A, Almkvist O. Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology. 1999;52:1861-1870.
105. Grady CL, Furey ML, Pietrini P, Horwitz B, Rapoport SI. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain. 2001;124:739-756.
106. Mentis MJ, Alexander GE, Krasuki J, et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry. 1998;155:785-794.
107. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450-456.
108. Smith CD, Andersen AH, Kryscio RJ, et al. Women at risk for AD show increased parietal activation during a fluency task. Neurology. 2002;58:1197-1202.
109. Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol. 1999;45:466-472.
110. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592-598.
111. 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging. 1999;17:291-299.
112. Doraiswamy PM, Charles HC, Rama Krishnan KR. Prediction of cognitive decline in early Alzheimer's disease. Lancet. 1998;352:1678.
113. 1H MRS study. Neurology. 2000;55:210-217.
114. Catani M, Cherubini A, Howard R, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 2001;12:2315-2317.
115. 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J Am Geriatr Soc. 1996;44:133-138.
116. Grossman RI, Gomori JM, Ramer KN, Lexa FJ, Schnall MD. Magnetization transfer: theory and clinical application in neuroradiology. Radiographics. 1994;14:279-290.
117. Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992;182:483-491.
118. Van Waesberghe JHTM, Kamphorst W, De Groot JA, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46:747-754.
119. Van der Flier WM, Van den Heuvel DM, Weverling-Rinjsburger AW, et al. Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology. 2002;59:874-879.
120. Van der Flier WM, Van den Heuvel DMJ, Weverling-Rinjsburger AWE, et al. Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann Neurol. 2002;52:62-67.
121. Kabani NJ, Sled JG, Chertkow H. Magnetization transfer ratio in mild cognitive impairment and dementia of Alzheimer's type. Neuroimage. 2002;1S:604-610.
122. Kabani NJ, Sled JG, Shuper A, Chertkow H. Regional magnetization transfer ratio changes in mild cognitive impairment. Magn Reson Med. 2002;47:143-148.
123. Hanyu H, Asano T, Iwamoto T, Takasaki M, Shindo H, Abe K. Magnetization transfer measurements of the hippocampus in patients with Alzheimer's disease, vascular dementia, and other types of dementia. AJNR Am J Neuroradiol. 2000;21:1235-1242.
124. Hanyu H, Asano T, Sakurai H, Takasaki M, Shindo H, Abe K. Magnetization transfer measurements of the hippocampus in the early diagnosis of Alzheimer's disease. J Neurol Sci. 2001;188:79-84.
125. Bozzali M, Franceschi M, Falini A, et al. Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. Neurology. 2001;57:1135-1137.
126. Strittmatter WJ, Saunders AM, Scmechel D, et al. Apolipoprotein E: high avidity binding to beta amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
127. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam study. Arch Neurol. 1998;55:964-968.
128. Chertkow H. Mild cognitive impairment. Curr Opin Neurol. 2002;15:401-407.
129. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149-154.
130. Jonker C, Schmand B, Lindenboom J, Havekes LM, Launer LJ Association between apolipoprotein E ε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol. 1998;1065-1069.
131. Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology. 2000;54:1492-1497.
132. Teunissen CE, de Vente J, Steinbuch HWM, De Bruijn C. Biocemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002;23:485-508.
133. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer's disease". Neurobiol Aging. 1998;19:109-116.
134. Rösler N, Wichart I, Jellinger KA. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm. 2001;108:231-246.
135. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch Neurol. 2001;58:373-379.
136. de Leon MJ, Segal S, Tarshish CY, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002;333:183-186.
137. Buerger K, Teipel SJ, Zinkowski R, et al. CSF-tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627-629.
138. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett. 1999;273:5-8.
139. 42 levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol. 2001;172:433-436.
140. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729-1734.
141. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ε4 during 14-month follow-up. Neurosci Lett. 1996;214:163-166.
142. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 2000;166:201-203.
143. Buccafusco JJ, Terry AV Jr. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther. 2000;295:438-446.
144. Sramek JJ, Veroff AE, Cutler NR. The status of ongoing trials for mild cognitive impairment. Exp Opin Invest Drugs. 2001;10:741-752.
145. Meyer JS, Li Y, Xu G, Thornby J, Chowdhury MH, Quach M. Feasability of treating mild cognitive impairment with cholinesterase inhibitors. Int J Geriatr Psychiatry. 2002;17:586-588.
146. Freo U, Pizzolato G, Dam M, Ori C, Battistin L. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J Neural Transm. 2002;109:857-870.
147. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry. 2001;158:1517-1519.
148. ® CXS16 in elderly participants with mild cognitive impairment. J Mol Neurosci. 2002;19:197-200.
149. Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol. 1997;54:1234-1240.
150. Newcomer JW, Farber NB, Olney JW. NMDA receptor function, memory, and brain aging. Dialogues Clin Neurosci. 2000;2:219-232.
151. Gilmor ML, Erickson JF, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 1999;411:693-704.
152. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyl transferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
153. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54(suppl 5):54-59.
154. Anstey K, Christensen H. Education, activity, health, blood pressure and apolipoprotein E as predictors of cognitive change in old age: a review. Gerontology. 2000;46:163-177.
155. Letenneur L, Launer U, Andersen K, et al. Education and the risk for Alzheimer's disease: sex makes a difference. Am J Epidemiol. 2000;151:1064-1071.
156. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1988-1992.